Physician profile
Daniel Buck
NPI 1629307087
$553.28
in general payments reported to CMS, 2019-2025
12 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.78 · 2024: $16.98 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $138.81 | 2025 | |
| Glaxosmithkline, LLC. | $86.08 | 2025 | Shingrix, Bexsero, Flulaval Quadrivalent |
| Astrazeneca Pharmaceuticals Lp | $84.03 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $54.42 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.99 | 2025 | Caplyta |
| Pfizer INC. | $32.95 | 2025 | |
| Lundbeck LLC | $27.96 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $23.81 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $19.07 | 2025 | |
| Viatris Specialty LLC | $18.15 | 2025 | Yupelri |
| Novo Nordisk INC | $17.03 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.